Real-world treatment outcomes and clinicopathologic and molecular determinants of response to first-line lenvatinib in patients with advanced follicular cell-derived thyroid cancer

Real-world treatment outcomes and clinicopathologic and molecular determinants of response to first-line lenvatinib in patients with advanced follicular cell-derived thyroid cancer

Abstract Background There is a paucity of real-world data regarding lenvatinib for locally-recurrent, metastatic and RAI-refractory thyroid cancer. Here we examined the efficacy of first-line lenvatinib in a genomically-characterized cohort and identified clinicopathological/molecular correlates of...

Full description

Saved in:
Bibliographic Details
Main Authors: Kara M. Ruicci, Yangqing Deng, Tian Xiao, Antoine Eskander, David Goldstein, Ozgur Mete, Aruz Mesci, Jelena Lukovic, Monika K. Krzyzanowska, Carly C. Barron, Lucy X. Ma
Format: Article
Language:English
Published: Nature Portfolio 2025-06-01
Series:BJC Reports
Online Access:https://doi.org/10.1038/s44276-025-00153-2
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1038/s44276-025-00153-2

Similar Items